Infliximab Biosimilar Insight 2023, by DelveInsight | Major players: Celltrion, Pfizer, Merck, Biocad, Celltrion

DelveInsight's "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of Biosimilars, visit @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Geography Covered: Global coverage

Infliximab Overview
Infliximab is a medication classified as a tumor necrosis factor (TNF) inhibitor. It is used for the treatment of various autoimmune diseases, particularly those involving chronic inflammation. Infliximab works by targeting and neutralizing tumor necrosis factor-alpha (TNF-α), a cytokine involved in the inflammatory response. By inhibiting TNF-α, Infliximab helps reduce inflammation and alleviate symptoms associated with certain autoimmune conditions.
Indications: Infliximab is commonly prescribed for conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. These are conditions where excessive TNF-α plays a role in perpetuating inflammation.
Administration: Infliximab is typically administered by intravenous infusion, usually in a healthcare setting such as a hospital or infusion center. The frequency of infusions may vary depending on the specific condition being treated.
Mechanism of Action: TNF-α is a pro-inflammatory cytokine involved in the immune response. By binding to TNF-α, Infliximab inhibits its activity, leading to a reduction in inflammation. This mechanism helps control the symptoms of autoimmune diseases and prevent further damage to tissues.

Efficacy: Infliximab has shown effectiveness in managing symptoms, improving quality of life, and slowing disease progression in various autoimmune disorders. However, it is not a cure, and its use requires careful monitoring and management by healthcare professionals.
Side Effects: Like many medications, Infliximab is associated with potential side effects. These can include an increased risk of infections, infusion reactions, and, in rare cases, serious adverse events. Patients receiving Infliximab are typically monitored closely for any signs of adverse reactions.

Precautions: Prior to starting Infliximab, healthcare providers consider the patient's medical history, including the presence of infections, and may perform screening tests. It is important for patients to inform their healthcare provider about any ongoing infections or other medical conditions before starting treatment.
Request for a detailed sample copy of our report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Infliximab Biosimilars: Marketed Drugs
1. Inflectra: Celltrion/Pfizer
2. Renflexis: Merck
Infliximab Biosimilars: Emerging Drugs
1. BCD 055: Biocad
2. CT-P17: Celltrion
Major Players in Infliximab

There are approximately 20+ Infliximab biosimilars key companies which are developing the therapies for Infliximab.
To understand key companies related to the Infliximab Biosimilars Market, get a snapshot @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Infliximab Biosimilars Report Highlights:
1. The companies and academics are working to assess challenges and seek opportunities that could influence Infliximab R&D. The therapies under development are focused on novel approaches to treat/improve Infliximab.
2. In July 2017, Merck had launched in the U.S. a biosimilar of Remicade (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including Europe, while partner Janssen Biotech markets the drug stateside.
3. In December 2017, Pfizer announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade (infliximab) for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

For detailed Infliximab Biosimilars Report Highlights, visit here @ https://www.delveinsight.com/report-store/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents:

1. Key Insights
2. Infliximab Biosimilars: Snapshot
3. Executive Summary
4. Regulatory Outlook For Biosimilars
5. Infliximab (Reference Product: Remicade)
6. Research and Development
7. Remicade Biosimilar: Emerging Opportunities
8. Infliximab: Biosimilars Assessment
9. Infliximab Biosimilars Profiles: By Company
10. Infliximab Biosimilars: Comparative Landscape: By Company
11. Infliximab Biosimilars: Competitive Landscape
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15. Appendix
16. Bibliography
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Reqest for a detailed TOC of the Infliximab Biosimilars Report @ https://www.delveinsight.com/sample-request/infliximab-biosimilars-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.